comparemela.com

Latest Breaking News On - Iziana life sciences kurs - Page 1 : comparemela.com

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today

19.04.2024 - - Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) Data presented in a platform session at the Annual Meeting of the American . Seite 1

Tarun singhalJohn corboyUniversity of colorado anschutz medical campusMountain multiple sclerosis centerImaging program in neurologic diseases at brighamProfessor of neurology at harvard medical schoolNeurologic diseasesMass general brigham healthcareAssociate professorHarvard medical schoolRocky mountain multiple sclerosis centerColorado anschutz medicalTiziana life sciences chartIziana life sciences kursIziana life sciences aktie

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

19.12.2023 - NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase . Seite 1

Gabriele cerroneMattheww davisTanuja chitnisTiziana life sciences ltdAccess programTiziana life sciencesProfessor of neurology at harvard medical schoolLife sciencesExpanded disability status scaleModified fatigue impact scalePrincipal investigatorMass general brigham healthcare systemHarvard medicalExpanded access programChief operating officerChief medical officer

Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab

16.10.2023 - Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL Fatigue scores.Data was presented at ECTRIMS . Seite 1

Research of multiple sclerosis onAccess ea programEuropean committee for treatmentTiziana life sciences ltdModified fatigue impact scaleExpanded disability status scaleFoot walkPyramidal scoresNeuroqol fatigueEuropean committeeMultiple sclerosisLife sciencesProgressive multiple sclerosisExpanded accessTiziana life sciences chartIziana life sciences kurs

Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

26.09.2023 - NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it .

Mattheww davisTiziana life sciencesTiziana life sciences ltdLife sciencesMass general brigham healthcare systemSecondary progressive multiple sclerosisChief operating officerChief medical officerExpanded accessTiziana life sciences chartIziana life sciences kursIziana life sciences aktie

Study Validating MoA of Intranasal Foralumab in Alzheimer s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance Seite 1

06.09.2023 - The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal . Seite 1

United statesHowardl weinerRobertl krocTiziana life sciences ltdHarvard medical schoolFounder of the partners multiple sclerosis centerProceedings of the national academy sciencesNasal administrationDrug administrationAnn romney centerLife sciencesNational academyPartners multiple sclerosis centerNeurologic diseasesMass general brigham healthcare systemScientific advisory board

vimarsana © 2020. All Rights Reserved.